<DOC>
	<DOCNO>NCT00775996</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability Ranbaxy Abbott ( TranxeneeT-Tab® ) 15 mg clorazepate dipotassium tablet fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single-dose , crossover , bioequivalence study clorazepate dipotassium compare clorazepate dipotassium 15mg tablet Ranbaxy Laboratories Abbott ( TranxeneeT-Tab® ) 15 mg , healthy , adult , human , subject fast condition . A total 32 subject , 25 male 7 female , enrol study , 31 subject , 24 male 7 female , complete study .</detailed_description>
	<mesh_term>Clorazepate Dipotassium</mesh_term>
	<criteria>Subjects include study meet follow criterion : 1 . Healthy adult male female volunteer , 1855 year age 2 . Weighing least 60 kg male 52 kg female within 15 % ideal weight 3 . ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) ; Medically healthy subject clinically normal laboratory profile ECGs deem principal investigator ; 4 . Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : surgically sterile ( bilateral ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum ; IUD place least 3 month ; barrier method ( condom , diaphragm ) spermicide time last menstrual period throughout study ; surgical sterilization partner ( vasectomy 6 month minimum ) ; hormonal contraceptive least 3 month prior first dose study . Postmenopausal woman amenorrhea least 1 year , confirm blood testing ( FSH level &gt; 40 international units/mL ) . Voluntarily consent participate study , Subjects exclude study evidence follow screening time study : History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse ; seizure ; g1aucoma ; hypersensitivity idiosyncratic reaction drug , especially clorazepate benzodiazepine . Female subject pregnant lactating . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Subjects make donation ( standard donation amount ) blood blood product ( exception plasma note ) within 56 day prior first dose . Subjects make plasma donation within 7 day prior first dose . Subjects participate another clinical trial within 28 day prior first dose . Subjects hemoglobin less 12_0 g/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>bioequivalence Clorazepate Tablets</keyword>
</DOC>